IncyteINCYEarnings & Financial Report
Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia.
INCY Q4 2025 Key Financial Metrics
Revenue
$1.5B
Gross Profit
$1.4B
Operating Profit
$335.9M
Net Profit
$299.3M
Gross Margin
92.0%
Operating Margin
22.3%
Net Margin
19.9%
YoY Growth
27.8%
EPS
$1.46
Financial Flow
Incyte Q4 2025 Financial Summary
Incyte reported revenue of $1.5B for Q4 2025, with a net profit of $299.3M (19.9% margin). Cost of goods sold was $121.2M, operating expenses totaled $1.0B.
Key Financial Metrics
| Total Revenue | $1.5B |
|---|---|
| Net Profit | $299.3M |
| Gross Margin | 92.0% |
| Operating Margin | 22.3% |
| Report Period | Q4 2025 |
Incyte Annual Revenue by Year
Incyte annual revenue history includes year-by-year totals (for example, 2025 revenue was $5.1B).
| Year | Annual Revenue |
|---|---|
| 2025 | $5.1B |
| 2024 | $4.2B |
| 2023 | $3.7B |
| 2022 | $3.4B |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $880.9M | $1.04B | $1.14B | $1.18B | $1.05B | $1.22B | $1.37B | $1.51B |
| YoY Growth | 8.9% | 9.3% | 23.8% | 16.3% | 19.5% | 16.5% | 20.0% | 27.8% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $7.14B | $4.66B | $5.01B | $5.44B | $5.75B | $5.82B | $6.33B | $6.96B |
| Liabilities | $1.74B | $1.66B | $1.84B | $2.00B | $2.08B | $1.65B | $1.68B | $1.79B |
| Equity | $5.39B | $3.00B | $3.17B | $3.45B | $3.67B | $4.17B | $4.65B | $5.17B |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $218.8M | $-575.6M | $310.9M | $381.2M | $266.1M | $44.7M | $559.4M | $543.3M |
Other Health Care Companies
ABBV
AbbVie
Revenue
$15.8B
Net Profit
$186.0M
AMGN
Amgen
Revenue
$9.9B
Net Profit
$1.3B
BIIB
Biogen
Revenue
$2.3B
Net Profit
$-48.9M
GILD
Gilead Sciences
Revenue
$7.8B
Net Profit
$3.1B
MRNA
Moderna
Revenue
$1.0B
Net Profit
$-200.0M
REGN
Regeneron Pharmaceuticals
Revenue
$3.9B
Net Profit
$844.6M
VRTX
Vertex Pharmaceuticals
Revenue
$3.2B
Net Profit
$1.2B
ABT
Abbott Laboratories
Revenue
$11.4B
Net Profit
$1.6B
A
Agilent Technologies
Revenue
$1.9B
Net Profit
$434.0M
ALGN
Align Technology
Revenue
$995.7M
Net Profit
$56.8M